Results 241 to 250 of about 1,015,430 (313)

To treat or not to treat young children with hepatitis C?--real-life experience. [PDF]

Eur J Pediatr
Pokorska-Śpiewak M, Dobrzeniecka A, Talarek E, Aniszewska M, Marczyńska M.   +4 more
europepmc   +1 more source

Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Votoplam is a novel, orally bioavailable, small molecule HTT gene splicing modifier that is being developed for the treatment of Huntington's disease. This was a single dose, open‐label, two‐period, crossover food effect study that evaluated the effect of high‐ and low‐fat meals on 20 mg votoplam in healthy participants. There was a washout of
Lucy Lee, Amy‐Lee Richards, Nageswara Reddy, Brian Beers, Lee Golden, Ronald Kong   +5 more
wiley   +1 more source

Pharmacokinetics of Sofosbuvir and Velpatasvir for Hepatitis C Treatment in Pregnancy. [PDF]

Biomedicines
Giles ML, Dunbar A, Krishnaswamy S, Sasadeusz J, Said JM, Roon L, Bushman LR, Brooks KM.   +7 more
europepmc   +1 more source

Nanoparticles in microdroplets: Recent advances in microfluidic generators for producing functional microbeads

Droplet, EarlyView.
Functional hybrid microbeads with electrical, magnetic, and/or optical responsiveness have emerged as versatile platforms for biotechnology. This review highlights recent advances in microfluidic technologies for producing such microbeads, with a focus on incorporating functional nanoparticles in microdroplet systems.
  Bayinqiaoge, Chengchen Zhang, Shi‐Yang Tang   +2 more
wiley   +1 more source

[Recent Advances in the Treatment of Chronic Hepatitis C]. [PDF]

Korean J Gastroenterol
Kim SB.
europepmc   +1 more source

Core protein cleavage by signal peptide peptidase is required for hepatitis C virus-like particle assembly

, 2006
Malika Ait‐Goughoulte, Christophe Hourioux, Romuald Patient, Sylvie Trassard, Denys Brand, Philippe Roingeard   +5 more
openalex   +2 more sources

Expression of mutant TIE2 p.L914F during mouse development causes embryonic lethality and defects in vascular remodeling

Developmental Dynamics, EarlyView.
Abstract Background Sporadic venous malformation (VM) is associated with the hyperactivating p.L914F mutation in TIE2, a receptor tyrosine kinase essential for vascular development. This mutation is not found in hereditary VM, suggesting incompatibility with life when expressed during early vascular development.
Lindsay J. Bischoff, Sandra Schrenk, Kara Soroko, Chhiring Sherpa, Ashok Arasu, Damien Reynaud, Elisa Boscolo   +6 more
wiley   +1 more source

Maternal Gestational Low‐Grade Inflammation and the Risk of Anorexia Nervosa in Daughters

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Prenatal exposures have been suggested to have a programming effect on neural and metabolic development, which may affect the risk of eating disorders. We investigated the association between prospectively measured maternal gestational high‐sensitivity C‐reactive protein (hs‐CRP), an established inflammatory biomarker, and subsequent
Emma Saure, Pyry N. Sipilä, Cynthia M. Bulik, Elina Santti, Heljä‐Marja Surcel, Antti Latvala, Anu Raevuori   +6 more
wiley   +1 more source

Economic evaluation of an employee health screening program for Hepatitis C virus in Pakistan. [PDF]

Cost Eff Resour Alloc
Qureshi A, Bolas T, Khan UI, Malik AM, Risko N.   +4 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source